Shares in Medacta Group SA do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend. Investors have an opportunity to buy the stock and target the CHF 179.
The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.31 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
ę MarketScreener.com 2021
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.